Project from my group & rheum-bound resident Mary Peng! As expected, ischemic vision loss for GCA compared to PMR (HR 5.4) and gen pop (HR 5.6) 😬 NO difference for PMR vs gen pop (aHR 1.10, 95% CI 0.86–1.41) Reassuring for pts w/PMR! #ACR25 @RheumNow Abstr#0753 #ACRBest https://t.co/HKzc7OOzmP

• https://x.com/EBRheum/status/1982494684107727105/photo/1

Avacopan in the real world: we need to be braver If we want to get steroid-sparing benefit in AAV, we need to trust it claims data shows modest PNL reduction with avacopan some manifestations are harder to taper in, but others we just need to be bolder #ACR25 ABST0726 @RheumNow https://t.co/51nGdpR2db

• https://x.com/drdavidliew/status/1982488060941213929/photo/1

#ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their remission (69%) vs those who switched to PBO after in remission for ≥24 weeks (29%). Lower serious infection but higher herpes zoster in UPA15. One VTE @RheumNow https://t.co/FCTNqCVxiZ

• https://x.com/Yuz6Yusof/status/1982486937022939200/photo/1
• https://x.com/Yuz6Yusof/status/1982486937022939200/photo/1

Lindberg et al. Nationwide case-control study in Sweden. Big increase in risk of DVT/PE in AAV, most marked early after diagnosis @RheumNow #ACR25 Abstr#718 https://t.co/FpDcbX15hm

• https://x.com/RichardPAConway/status/1982483107790872801/photo/1

Heydari-Kamjani et al. Risk of DILI with avacopan. Real world study, propensity score matching. Risk DILI 2% with avacopan vs 1.9% PBO @RheumNow #ACR25 Abstr#724 https://t.co/UhVkcXEYjF

• https://x.com/RichardPAConway/status/1982482352962998313/photo/1

Ogdie et al. Week 24 results of SOLSTICE study. Guselkumab in TNF-IR in PsA. Good efficacy on skin and joint disease. No difference seen in Q4 vs Q8 weekly doses. @RheumNow #ACR25 Abstr#563 https://t.co/ztK0O9iKb8

• https://x.com/RichardPAConway/status/1982481346682396779/photo/1

Observational study of fibrinogen for diagnosis of GCA At a cutoff of 4.7, roughly similar diagnostic performance as compared to ESR/CRP Kind of neat, but does not appear to have additive benefit #ACR25 @RheumNow Abstr#0750 https://t.co/xy2qn4jHXP

• https://x.com/EBRheum/status/1982481345915040253/photo/1

Abstract 0806 Compared to belimumab, Anifrolumab associated with: ↑ infection risk b (HR 1.40, 95% CI 1.05–1.88) ↑ herpes zoster (HR 3.94) & COVID-19 (HR 1.66) No diff in mortality or hospital use 📈 3-yr infection: 38.3% vs 21.3% @RheumNow #ACR25

Real world effectiveness of voclosporin for SLE Reduction in UPCR from 2.1 at b/l to 0.9 at 6 months, no improvement in eGFR; as expected based on trials Wonder about market share of BEL vs voclo vs ANI - anyone seen pubs on this? #ACR25 @RheumNow Abstr#0661 https://t.co/l7i7IWhLSe

• https://x.com/EBRheum/status/1982478074810662970/photo/1

Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA and RF disappeared. Results maybe not as positive as we might have anticipated? @RheumNow #ACR25 Abstr#471 https://t.co/TaEVWiWsNm

• https://x.com/RichardPAConway/status/1982477067988992375/photo/1

#0776 In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO, cutting flare risk by 90% and reducing steroid exposure by ~1g. No new safety signals in older adults (mean 71yrs). @RheumNow #ACR25 https://t.co/KC9sm3ic3q

• https://x.com/DrMiniDey/status/1982476564739620938/photo/1

Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per 100PY. @RheumNow #ACR25 Abstr#585 https://t.co/g78zUsxD5a

• https://x.com/RichardPAConway/status/1982476060890649026/photo/1

Post-hoc PEXIVAS study, estimating risk of relapse from baseline variables Lotsa fancy stats, mostly corroborated known risk factors, but model predicted relapse reasonably well! Probably useful for approach to monitoring... mayyybe treatment? #ACR25 @RheumNow #Abstr0722 https://t.co/XI9y8KgDNR

• https://x.com/EBRheum/status/1982474802700140629/photo/1
• https://x.com/EBRheum/status/1982474802700140629/photo/1
• https://x.com/EBRheum/status/1982474802700140629/photo/1

Statins and SLE: To add or not to add? 💊 Abstract #0599: In an emulated target trial of patients with SLE, statin users vs non-users had significantly⬇️ risk of all-cause death in both ITT & per-protocol analyses. - No significant differences in MACE or ESKD. @RheumNow #ACR25

Plenary 1: SELECT-GCA (RCT, UPA vs PLBO in GCA) Pts in remission re-randomized at wk52 Higher maintenance of remission in pts who continued UPA15 (69%) vs switchers from UPA15->PLBO (29%) Argues strongly for continuing tx in GCA for >1yr! @RheumNow #ACR25 Ab#0776 #ACRBest https://t.co/exmmIcpgbP

• https://x.com/EBRheum/status/1982473544505372756/photo/1
• https://x.com/EBRheum/status/1982473544505372756/photo/1